Carboplatin-Paclitaxel Versus Cisplatin-Ifosfamide in the Treatment of Uterine Carcinosarcoma: A Retrospective Cohort Study

Lorusso, Domenica; Martinelli, Fabio; Mancini, Maria; Sarno, Italo; Ditto, Antonino; Raspagliesi, Francesco

doi:10.1097/igc.0000000000000215

Cited by 11 publications

(8 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As with ixabepilone for EC treatment, a nearly identical and modest response rate (12%), median PFS 1.7 months), and OS (7.7 months) were seen in 34 patients with uterine carcinosarcoma in the GOG-130F study [ 66 ]. Furthermore, as with treatment of other ECs, the use of CT in uterine carcinosarcoma is an appropriate option based on apparent equivalent efficacy and better tolerability [ 67 ].…”

Section: Reviewmentioning

confidence: 99%

“…Luteinizing hormone-releasing hormone receptors (LHRH-Rs) mediate antiproliferative activity in endometrial cell lines, and approximately 80% of ECs express LHRH-Rs, offering a potentially useful target in these tumors [ 66 , 67 ]. Zoptarelin doxorubicin is an [D-Lys6]LHRH linked to doxorubicin, with activity in LHRH-R-positive cancer cell lines [ 72 , 73 ].…”

Section: Reviewmentioning

confidence: 99%

See 1 more Smart Citation

New therapies for advanced, recurrent, and metastatic endometrial cancers

Makker

Green

Wenham

et al. 2017

gynaecol oncol res pract

View full text Add to dashboard Cite

Endometrial cancer is the most common gynecologic malignancy in the United States, accounting for 6% of cancers in women. In 2017, an estimated 61,380 women were diagnosed with endometrial cancer, and approximately 11,000 died from this disease. From 1987 to 2008, there was a 50% increase in the incidence of endometrial cancer, with an approximate 300% increase in the number of associated deaths. Although there are many chemotherapeutic and targeted therapy agents approved for ovarian, fallopian tube and primary peritoneal cancers, since the 1971 approval of megestrol acetate for the palliative treatment of advanced endometrial cancer, only pembrolizumab has been Food and Drug Administration (FDA)-approved for high microsatellite instability (MSI-H) or mismatch repair deficient (dMMR) endometrial cancer; this highlights the need for new therapies to treat advanced, recurrent, metastatic endometrial cancer. In this review, we discuss current and emerging treatment options for endometrial cancer, including chemotherapy, targeted therapy, and immunotherapy. The National Cancer Institute (NCI) and others are now focusing their efforts on the design of scientifically rational targeted therapy and immunotherapy trials for specific molecular phenotypes of endometrial cancer. This is essential for the advancement of cancer care for women, which is threatened by a severe enrollment decline of approximately 80% for gynecologic oncology clinical trials.

show abstract

Section: Reviewmentioning

confidence: 99%

Section: Reviewmentioning

confidence: 99%

New therapies for advanced, recurrent, and metastatic endometrial cancers

Makker

Green

Wenham

et al. 2017

gynaecol oncol res pract

View full text Add to dashboard Cite

show abstract

“…Recently, some authors have considered carcinosarcoma as de‐differentiated endometrioid adenocarcinoma . Despite the fact that ifosfamide/paclitaxel regimen is recommended by the guidelines for this group, these authors (who accept this group as de‐differentiated endometrioid adenocarcinoma) have offered adjuvant carboplatin/paclitaxel regimen . In our study, ifosfamide/paclitaxel regimen was administered to the entire carcinosarcoma group of patients who received adjuvant chemotherapy.…”

Section: Discussionmentioning

confidence: 97%

Combination of adjuvant chemotherapy and radiotherapy is associated with improved survival at early stage type II endometrial cancer and carcinosarcoma

Sözen

Çiftçi

Vatansever

et al. 2016

Aust N Z J Obstet Gynaecol

View full text Add to dashboard Cite

show abstract

“…Malignant mixed Müllerian tumors (MMMT), widely known as carcinosarcomas, are extremely rare and highly malignant neoplasms when diagnosed in the female genital tract ( 1 ). Field literature recognizes the uterus, cervix and ovary as the most common primary sites of these malignancies ( 2 ). While the endometrium is the most frequent known site for carcinosarcomas, their development in the fallopian tube is a rare condition, only accounting for 0.1 to 0.5% among all gynecological malignancies ( 3 , 4 ).…”

Section: Introductionmentioning

confidence: 99%

Malignant mixed Müllerian tumor of the fallopian tube: Case report and literature review

et al. 2021

View full text Add to dashboard Cite

Carcinosarcoma, also known as malignant mixed Müllerian tumor (MMMT), includes both malignant epithelial and mesenchymal elements. While the endometrium is the most frequent known site for carcinosarcomas, their development in the fallopian tube is rare condition, only accounting for 0.1 to 0.5% among all gynecological malignancies. Fallopian tube MMMT is associated with an aggressive progression. A total of 94 previous case reports were reviewed and divided, after applying the exclusion criteria, into 2 groups: No evidence of disease (NED) Group including 33 patients reported to be without any residual disease at the end of the follow-up period; death of disease (DOD) Group including 51 patients who died due to the progression of fallopian carcinosarcoma or its complications. The gathered data were statistically analyzed together with a case from our clinical experience: a 65-year-old postmenopausal patient with a final histological diagnosis of fallopian carcinosarcoma staged FIGO IC2, synchronous with a serous endometrial intraepithelial carcinoma. Patient age between 41 and 60 years, symptoms at presentation and computed tomography (CT)/magnetic resonance imaging (MRI) tumor evidence are prognostic factors (P<0.05). Omentectomy [odds ratio (OR)=0.3545] and pelvic lymphadenectomy (OR= 0.3732) were found to be significant factors for survival (P<0.05). Fimbrial localization of the tumor is a negative prognosis factor (OR=4.263), as well as the heterologous type of tumor (OR=2.880). Chemotherapy was found to improve survival (OR=0.2679) while radiotherapy had no influence on patient prognosis. Reporting these rare cases could be essential for obtaining more precise information regarding the treatment and prognosis of patients with MMMT of the fallopian tube, in order to improve patient survival and quality of life.

show abstract

Carboplatin-Paclitaxel Versus Cisplatin-Ifosfamide in the Treatment of Uterine Carcinosarcoma: A Retrospective Cohort Study

Abstract: Because of the super imposable activity and the better toxicity profile, carboplatin-paclitaxel may be a suitable alternative to cisplatin-ifosfamide in the treatment of uterine CS.

Cited by 11 publications

References 26 publications

New therapies for advanced, recurrent, and metastatic endometrial cancers

New therapies for advanced, recurrent, and metastatic endometrial cancers

Combination of adjuvant chemotherapy and radiotherapy is associated with improved survival at early stage type II endometrial cancer and carcinosarcoma

Malignant mixed Müllerian tumor of the fallopian tube: Case report and literature review

Contact Info

Product

Resources

About